DE60123752D1 - Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau - Google Patents

Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau

Info

Publication number
DE60123752D1
DE60123752D1 DE60123752T DE60123752T DE60123752D1 DE 60123752 D1 DE60123752 D1 DE 60123752D1 DE 60123752 T DE60123752 T DE 60123752T DE 60123752 T DE60123752 T DE 60123752T DE 60123752 D1 DE60123752 D1 DE 60123752D1
Authority
DE
Germany
Prior art keywords
tau
phospho
diagnosis
ratio
tauopathia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60123752T
Other languages
English (en)
Other versions
DE60123752T2 (de
Inventor
Eugeen Vanmechelen
Hugo Vanderstichele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Publication of DE60123752D1 publication Critical patent/DE60123752D1/de
Application granted granted Critical
Publication of DE60123752T2 publication Critical patent/DE60123752T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
DE60123752T 2000-01-24 2001-01-18 Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau Expired - Lifetime DE60123752T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP00870008 2000-01-24
EP00870008 2000-01-24
US17839100P 2000-01-27 2000-01-27
US178391P 2000-01-27
EP00870280 2000-11-22
EP00870280 2000-11-22
PCT/EP2001/000560 WO2001055725A2 (en) 2000-01-24 2001-01-18 Diagnosis of tauopathies determining tau/phospho-tau ratio

Publications (2)

Publication Number Publication Date
DE60123752D1 true DE60123752D1 (de) 2006-11-23
DE60123752T2 DE60123752T2 (de) 2007-08-23

Family

ID=27223742

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1250600T Pending DE1250600T1 (de) 2000-01-24 2001-01-18 Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau
DE60123752T Expired - Lifetime DE60123752T2 (de) 2000-01-24 2001-01-18 Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE1250600T Pending DE1250600T1 (de) 2000-01-24 2001-01-18 Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau

Country Status (13)

Country Link
US (2) US6680173B2 (de)
EP (1) EP1250600B1 (de)
JP (1) JP5247963B2 (de)
AT (1) ATE342509T1 (de)
AU (1) AU777837B2 (de)
BR (1) BR0107851A (de)
CA (1) CA2397991C (de)
CY (1) CY1107993T1 (de)
DE (2) DE1250600T1 (de)
DK (1) DK1250600T3 (de)
ES (1) ES2274869T3 (de)
HK (1) HK1048513B (de)
WO (1) WO2001055725A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162230A1 (en) * 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
JP4681175B2 (ja) * 2001-09-28 2011-05-11 三菱化学メディエンス株式会社 播種性血管内凝固症候群及びその発症前段階を検出する方法
JP4393382B2 (ja) * 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
EP1606404A4 (de) * 2003-03-12 2006-04-12 Assay Designs Inc Phosphokinasetest
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7238788B2 (en) * 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
JP4730584B2 (ja) 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
WO2007068105A1 (en) * 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
EP2326339A4 (de) * 2008-05-21 2012-06-20 Neurotez Inc Verfahren zur behandlung von progressiven kognitiven störungen im zusammenhang mit neurofibrillären tangles
US8648044B2 (en) * 2009-09-24 2014-02-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) FKBP52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
WO2011109112A2 (en) * 2010-03-05 2011-09-09 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
US20130052669A1 (en) * 2010-04-30 2013-02-28 Amanda G. Paulovich Compositions and methods for reliably detecting and/or measuring the amount of a modified target protein in a sample
CA2826286C (en) * 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
BR112015003326A2 (pt) 2012-08-16 2017-07-04 Ipierian Inc métodos de tratamento de uma tauopatia
EP2893042B1 (de) * 2012-09-05 2018-02-14 Emory University Diagnostische tests bei demenz und zugehörige verfahren
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
ES2800827T3 (es) 2013-06-10 2021-01-04 Ipierian Inc Procedimientos de tratamiento de una tauopatía
SI3083680T1 (sl) 2013-12-20 2020-06-30 F. Hoffmann-La Roche Ag Humanizirana protitelesa proti beljakovini Tau(pS422) in postopki uporabe
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
CN106605146B (zh) * 2014-04-08 2020-07-28 佛罗里达大学研究基金会有限公司 用于中枢神经***的急性、亚急性和慢性创伤性损伤的蛋白质标志物
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
DE102014013571A1 (de) * 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoklonaler Antikörper gegen humanes TAU-Protein
CN113929779A (zh) 2015-06-24 2022-01-14 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
KR102033776B1 (ko) * 2017-10-31 2019-10-17 가천대학교 산학협력단 타우 단백질의 발현수준을 측정하는 제제를 포함하는 알츠하이머 중증도 진단용 조성물 및 이를 이용한 알츠하이머 중증도의 진단방법
JOP20200215A1 (ar) 2018-03-05 2020-09-03 Janssen Pharmaceutica Nv الأجسام المضادة لـ PHF-Tau المضاد واستخداماتها
EP3885362A4 (de) * 2018-11-22 2022-08-17 Fujirebio Inc. Antikörperkonjugat
WO2020193500A1 (en) * 2019-03-28 2020-10-01 H. Lundbeck A/S Use of a ps396 assay to diagnose tauophaties
US11155609B2 (en) 2019-04-05 2021-10-26 TauC3 Biologies Limited Anti-TAUC3 antibodies and uses thereof
BR112021021062A2 (pt) * 2019-05-31 2021-12-14 Lilly Co Eli Compostos e métodos que alvejam tau humano
CA3168823A1 (en) * 2020-02-05 2021-08-12 Sumitomo Pharma Co., Ltd. Determination agent and determination method for tauopathy and dementia-related diseases
WO2023135201A1 (en) * 2022-01-12 2023-07-20 Gtinvent Limited Method for detecting a tau protein fragment in a sample

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600951A4 (en) * 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
DK0673418T3 (da) * 1992-12-14 1999-03-01 Innogenetics Nv Monoklonale antistoffer rettet mod mikrotubulusassocieret tau-protein, hybridomaer, der secernerer disse antistoffer, antig
JPH06239899A (ja) * 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
EP0737208B1 (de) * 1993-12-21 2006-08-02 Innogenetics N.V. Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen
JPH10506381A (ja) * 1994-07-29 1998-06-23 イノジェネティックス・ナムローゼ・フェンノートシャップ 特定のサブクラスまたは形態のホスホリレーションされたｔａｕのエピトープに特異的なモノクローナル抗体、それらを分泌するハイブリドーマ、これらの抗体の抗原認識およびそれらの応用
WO1997034145A1 (fr) * 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1999062548A1 (en) * 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies

Also Published As

Publication number Publication date
US20030194742A1 (en) 2003-10-16
DK1250600T3 (da) 2007-02-05
US7387879B2 (en) 2008-06-17
JP5247963B2 (ja) 2013-07-24
EP1250600B1 (de) 2006-10-11
CY1107993T1 (el) 2013-09-04
AU3731901A (en) 2001-08-07
HK1048513B (zh) 2007-12-07
ATE342509T1 (de) 2006-11-15
WO2001055725A3 (en) 2001-12-20
WO2001055725A2 (en) 2001-08-02
ES2274869T3 (es) 2007-06-01
HK1048513A1 (en) 2003-04-04
BR0107851A (pt) 2002-10-29
CA2397991A1 (en) 2001-08-02
US6680173B2 (en) 2004-01-20
JP2003521499A (ja) 2003-07-15
CA2397991C (en) 2017-10-24
DE60123752T2 (de) 2007-08-23
DE1250600T1 (de) 2003-03-06
US20040091942A1 (en) 2004-05-13
AU777837B2 (en) 2004-11-04
EP1250600A2 (de) 2002-10-23

Similar Documents

Publication Publication Date Title
ATE342509T1 (de) Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau
NO973444L (no) Fremgangsmåter og forbindelser for magnetrelaksometrisk påvisning av analytter, samt anvendelse av slike
ATE394658T1 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
WO2002027326A3 (en) Method and kit for the transderaml determination of analyte concentration in blood
ATE312349T1 (de) Differentielle diagnose von neurodegeneration
BR9710836A (pt) Ensaio de analitos usando marcas em partìculas
ATE406578T1 (de) Candida-nachweis
ITTO20010411A0 (it) Metodo e dispositivo per l'esecuzione di test e saggi ad alta processivita' ed alto valore biologico su cellule e/o composti.
SE0400191D0 (sv) A test kit for detecting periodontal disease
ATE540319T1 (de) Verfahren für die bestimmung von fk506
DE60117592D1 (de) Diagnose von pre-eclampsia
KR950018482A (ko) 혈소판 응집 측정방법
WO2004094675A3 (en) Compositions and methods for determining the presence of sars coronavirus in a sample
ES2068599T3 (es) Procedimiento de reduccion de interferencias en un dosificado por fluorescencia.
WO2003084384A3 (en) Diagnosis of flavivirus infection
FI20011168A0 (fi) Menetelmä infektion laadun määrittämiseksi
WO2000026251A3 (en) A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX
WO2002059600A3 (en) Analyte detection
WO2004029216A3 (en) Diagnosis of invasive mold infection
DE60236849D1 (de) Diagnose von atherosclerose
DE60126991D1 (de) Verfahren ZUR DIAGNOSE VON SCHIZOPHRENIE
DE69912453D1 (de) Verfahren und materialien zur diagnose instabiler angina
WO2002050543A3 (en) Free analyte detection system
TR200402036T4 (tr) (-)-Cis-2-(2-Klorofenil)-5, 7-Dihidroksi-8-[4R-(3S-Hidroksi-1-Metil) Piperidinil]-4H-1- Benzopiran-4-on'un psödopolimorfu
DK1297342T3 (da) Metode til diagnostisk bestemmelse af Alzheimer's sygdom på basis af holo-transcobalamin II

Legal Events

Date Code Title Description
8364 No opposition during term of opposition